InsiderTrades.com logo
AI “wealth window” is closing soon!
From Paradigm Press   |   Ad
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
I put together this personal video [HERE]…
Glenn Sblendorio net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Glenn Sblendorio Biography and Net Worth

CEO of IVERIC bio
Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

What is Glenn Sblendorio's net worth?

The estimated net worth of Glenn Sblendorio is at least $9.12 million as of January 3rd, 2023. Mr. Sblendorio owns 228,191 shares of IVERIC bio stock worth more than $9,116,230 as of April 18th. This net worth evaluation does not reflect any other investments that Mr. Sblendorio may own. Additionally, Mr. Sblendorio receives an annual salary of $1,360,000.00 as CEO at IVERIC bio. Learn More about Glenn Sblendorio's net worth.

How old is Glenn Sblendorio?

Mr. Sblendorio is currently 67 years old. There are 5 older executives and no younger executives at IVERIC bio. Learn More on Glenn Sblendorio's age.

What is Glenn Sblendorio's salary?

As the CEO of IVERIC bio, Inc., Mr. Sblendorio earns $1,360,000.00 per year. Learn More on Glenn Sblendorio's salary.

How do I contact Glenn Sblendorio?

The corporate mailing address for Mr. Sblendorio and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on Glenn Sblendorio's contact information.

Has Glenn Sblendorio been buying or selling shares of IVERIC bio?

Glenn Sblendorio has not been actively trading shares of IVERIC bio within the last three months. Most recently, Glenn Sblendorio sold 17,447 shares of the business's stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $20.06, for a transaction totalling $349,986.82. Following the completion of the sale, the chief executive officer now directly owns 228,191 shares of the company's stock, valued at $4,577,511.46. Learn More on Glenn Sblendorio's trading history.

Who are IVERIC bio's active insiders?

IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Anthony Gibney (EVP), Calvin Roberts (Director), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.

Are insiders buying or selling shares of IVERIC bio?

During the last year, insiders at the sold shares 8 times. They sold a total of 193,500 shares worth more than $6,752,270.65. The most recent insider tranaction occured on July, 3rd when COO Keith Westby sold 20,000 shares worth more than $789,000.00. Insiders at IVERIC bio own 2.7% of the company. Learn More about insider trades at IVERIC bio.

Information on this page was last updated on 7/3/2023.

Glenn Sblendorio Insider Trading History at IVERIC bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2023Sell17,447$20.06$349,986.82228,191View SEC Filing Icon  
12/19/2022Sell19,457$21.51$418,520.07244,138View SEC Filing Icon  
11/2/2022Sell50,000$23.01$1,150,500.00179,689View SEC Filing Icon  
4/4/2022Sell50,000$18.76$938,000.00229,689View SEC Filing Icon  
4/1/2022Sell40,756$17.50$713,230.00View SEC Filing Icon  
3/30/2022Sell1,213$17.00$20,621.00View SEC Filing Icon  
3/25/2022Sell18,775$17.06$320,301.50View SEC Filing Icon  
3/18/2022Sell3,479$17.00$59,143.00View SEC Filing Icon  
12/27/2021Sell5,229$16.64$87,010.56View SEC Filing Icon  
12/23/2021Sell31,084$16.96$527,184.64View SEC Filing Icon  
12/20/2021Sell18,524$15.44$286,010.56View SEC Filing Icon  
12/13/2021Sell8,293$14.74$122,238.82View SEC Filing Icon  
12/10/2019Buy62,500$5.64$352,500.00176,854View SEC Filing Icon  
11/15/2019Buy15,000$3.12$46,800.00View SEC Filing Icon  
5/10/2019Buy25,000$1.48$37,000.00View SEC Filing Icon  
See Full Table

Glenn Sblendorio Buying and Selling Activity at IVERIC bio

This chart shows Glenn Sblendorio's buying and selling at IVERIC bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IVERIC bio Company Overview

IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Read More

Today's Range

Now: $39.95
Low: $39.95
High: $39.95

50 Day Range

MA: $38.88
Low: $36.90
High: $39.95

2 Week Range

Now: $39.95
Low: $9.39
High: $39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06
AI “wealth window” is closing soon!
From Paradigm Press   |   Ad
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
I put together this personal video [HERE]…